A Phase 2 interventional study of Methionine in Brain Tumors and/or Solid Tumors Including, Brain Stem Glioma and High Grade CNS Tumors, sponsored by St. Jude Children's Research Hospital. Active, not recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-06-17.
Sponsored by St. Jude Children's Research Hospital · Phase 2, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 182 studies in Ependymoma with a site in United States — 16 open to participants now, 42 under way, none of them phase 3. Ependymoma · United States.
Among the 182 studies in Ependymoma with a site in United States, this one is the 2nd largest by enrollment of the 155 interventional ones that give a count, is one of 7 that started in 2009, is one of 60 in phase 2, reaches primary completion later than 22 of the 40 other live ones, and was the 59th registered.
224 studies on the registry are indexed under Ependymoma; 35 are open to participants now.
Browse Ependymoma studies →16 of the 182 studies in Ependymoma with a site in United States are open now. Recruiting first, the newest first:
Robbie Majzner · Sites in United States
Ages 2–21
Cerenome · Sites in United States
Ages 6–21
University of Colorado, Denver · Sites in United States
Ages 18+
Children's National Research Institute · Sites in United States
Ages 1–30
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 25 Ependymoma studies recruiting now, 7 (28%) set no upper age limit and 16 (64%) stop at 75 or younger; 19 take children under 18; 1 takes healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
182 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 92 · Phase 2 72 · Phase 3 4
First in 1966; this study’s year is marked. 7 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 503 is above the median of 28 across 174 interventional studies indexed under Ependymoma.
Median enrollment 24 across the 155 interventional studies, 76 across the 13 observational. Of the 133 that completed or were terminated, 45 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 182 have an industry lead sponsor. The 10 most frequent:
St. Jude Children's Research Hospital is the lead sponsor of 441 studies on the registry; 103 are open to participants now.
Of its 61 completed or terminated interventional studies of FDA-regulated products, 37 (61%) have results posted.
St. Jude Children's Research Hospital has 6 studies filed under Ependymoma — fewer than ten, so there is no comparison to draw.
9 of the studies in Ependymoma with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03152318Dana-Farber Cancer InstituteA Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 | 2027-01 |
| NCT04661384City of Hope Medical CenterBrain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma | 2027-01-12 |
| NCT04541082Jazz PharmaceuticalsPhase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | 2027-03-31 |
| NCT04185038Seattle Children's HospitalStudy of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors | 2027-05 |
| NCT04732065Sabine Mueller, MD, PhDONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors | 2027-05-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 182 studies in Ependymoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to test the usefulness of imaging with radiolabeled methionine in the evaluation of children and young adults with tumor(s). Methionine is a naturally occurring essential amino acid. It is crucial for the formation of proteins. When labeled with carbon-11 (C-11), a radioactive isotope of the naturally occurring carbon-12, the distribution of methionine can be determined noninvasively using a PET (positron emission tomography) camera. C-11 methionine (MET) has been shown valuable in the monitoring of a large number of neoplasms. Since C-11 has a short half life (20 minutes), MET must be produced in a facility very close to its intended use. Thus, it is not widely available and is produced only at select institutions with access to a cyclotron and PET chemistry facility. With the new availability of short lived tracers produced by its PET chemistry unit, St. Jude Children's Research Hospital (St. Jude) is one of only a few facilities with the capabilities and interests to evaluate the utility of PET scanning in the detection of tumors, evaluation of response to therapy, and distinction of residual tumor from scar tissue in patients who have completed therapy. The investigators propose to examine the biodistribution of MET in patients with malignant solid neoplasms, with emphasis on central nervous system (CNS) tumors and sarcomas. This project introduces a new diagnostic test for the noninvasive evaluation of neoplasms in pediatric oncology. Although not the primary purpose of this proposal, the investigators anticipate that MET studies will provide useful clinical information for the management of patients with malignant neoplasms.
The study focuses on the following objectives:
Primary objective:
Secondary objective:
Exploratory objectives:
Inclusion Criteria:
Exclusion Criteria:
Inclusion Criteria for Open-Access
Exclusion Criteria for Open-Access
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who meet the eligibility criteria in the study will receive methionine.
Drug: Methionine
Intravenous injection
Also known as: MET, [11C]-L-Methionine
Success rate of methionine (MET) for visualizing tumors
To estimate the success rate of methionine (MET) for visualizing tumors at the time of diagnosis. We hypothesize that at least 70% of tumors within each group studied will be successfully visualized.
Time frame: Baseline
Association of methionine uptake with tumor grade
Methionine uptake in tumors will be compared among tumor grades in patients with newly diagnosed or relapsed, and/or persistent disease. Hypothesis: high-grade tumors will concentrate higher amounts of MET than lower-grade tumors measured both qualitatively and semi-quantitatively.
Time frame: End of study (maximum of 3 years post methionine infusion and PET scan)
Bio-distribution of MET in organs
Whole body scans will be acquired and descriptive statistics for MET uptake from other parts of the body will be provided.
Time frame: At baseline, after enrollment of the first 93 participants
PDFs hosted by the registry, ClinicalTrials.gov.
Started Jul 2009 (actual). Primary completion is estimated for Jul 2027, 216 months after the start.
Of 34 non-industry phase 2 interventional studies under Ependymoma, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 47 and three quarters within 108. This study's planned 216 months is above that.
Counting every sponsor, half of 35 studies reached it within 67 months; a quarter within 52 and three quarters within 108.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methionine
St. Jude Children's Research Hospital →